Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States

Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States

Background: Clinical trials have established calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam as a well-tolerated and efficacious topical therapy for psoriasis. Methods: A chart review of 24 US healthcare providers gathered real-world information (clinical characteristics and out...

Full description

Bibliographic Details
Main Authors: Jashin J. Wu, Karen A. Veverka, Minyi Lu, April W. Armstrong
Format: Article
Language:English
Published: Taylor & Francis Group 2019-07-01
Series:Journal of Dermatological Treatment
Subjects:
calcipotriene
betamethasone dipropionate
foam
real-world
psoriasis
itch
Online Access:http://dx.doi.org/10.1080/09546634.2018.1535689

Similar Items

Similar Items